ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Biohaven Reports Positive Results from BHV-0223 Trial
americanpharmaceuticalreview
August 17, 2018Biohaven announced positive results from a double-blind, placebo-controlled, proof of concept clinical trial evaluating the effect of BHV-0223 in patients diagnosed with social anxiety disorder and public speaking anxiety while performing an anxiety-provo -
Biohaven Doses First Subject in Bioequivalence Study with BHV-0223
americanpharmaceuticacreview
November 07, 2017Biohaven is developing BHV-0223, a sublingual formulation of riluzole, as a potential treatment for patients with Amyotrophic Lateral Sclerosis (ALS).
Pharma Sources Insight January 2025
